Major German Insurance Company in AOK Group Initiates Reimbursement Coverage of Theraclion’s Echotherapy

Regulatory News:

THERACLION (Paris:ALTHE) (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced that Allgemeine Ortskrankenkasse (AOK) Bremen/Bremerhaven, a major German insurance company, has signed an agreement to cover the reimbursement of echotherapy for the non-surgical treatment of both thyroid nodules and breast fibroadenomas.

The agreement covers echotherapy treatment performed at the Center for Nuclear Medicine and PET/CT in Bremen, which is the first and currently only center providing the non-invasive echotherapy procedure to patients with thyroid nodules or, in cooperation with their partner St. Joseph-Stift Hospital, to patients with breast fibroadenomas, thus completing the nuclear medicine care offer since 2016.

"We believe that it is important to provide procedures that minimize invasiveness, cost, patient discomfort and inconvenience without compromising efficacy whenever possible,” said Norbert Czech, M.D., Federal of the European Board of Nuclear Medicine, Center for Nuclear Medicine and PET/CT in Bremen. "Theraclion’s echotherapy system provides these benefits enabling us to offer optimal treatment for our patients.”

The AOK Bremen/Bremerhaven is the biggest insurer in the federal state of Bremen and covers approximately 237,000 members, 13,000 employers and 4,000 health care partners. AOK Bremen/Bremerhaven is one of eleven regional branches of AOK, which is the largest insurance group in Germany, covering more than 24.7 million people or approximately one-third of the German population.

José Abellan, Vice President, Central Europe Theraclion said, "This agreement between the Bremen Echotherapy Center and the AOK Bremen/Bremerhaven is of particular significance for patient access. AOK Bremen/Bremerhaven is the first insurer with significant regional coverage and marks a potential door opener to other members of the AOK group.”

Anja Kleber, VP of Marketing and Market Access Theraclion added, "Overall there now are over 1.7 million people covered by the public healthcare system in Germany. In addition to this coverage many public and private insurers also accept to reimburse the treatment by echotherapy on a case-by-case basis.”

David Caumartin, CEO of Theraclion added, "Our continuing success in accessing the German market clearly demonstrates that more payors agree to accept the recent scientific results and benefits shown by our Echopulse® echotherapy system.”

About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 34 people, half of it are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.

Theraclion is listed on Alternext Paris
PEA-PME eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402

View source version on businesswire.com: http://www.businesswire.com/news/home/20160906006090/en/